search
Back to results

Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia (LAL2317)

Primary Purpose

Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor

Status
Active
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
Chemotherapy + Blinatumomab
Sponsored by
Gruppo Italiano Malattie EMatologiche dell'Adulto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Lymphoid Leukemia focused on measuring Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor, Adults, Minimal residual disease, Blinatumomab

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed written informed consent according to ICH/EU/GCP and national local laws.
  • Age 18-65 years.
  • A diagnosis of untreated Ph- CD19+ BCP ALL is required, either de novo or secondary to chemo-radiotherapy for another cancer. Pre-treatment with low-dose corticosteroids in patients presenting with hyperleukocytosis is allowed. Before enrolment and pre-phase is allowed only in patients presenting with severe, potentially life-threatening disease-related clinical symptoms. All diagnostic procedures need to be performed on freshly obtained bone marrow (BM) and peripheral blood (PB) samples.
  • Full cytological, cytochemical, immunophenotypic, cytogenetic and molecular disease characterization according to the EGIL and WHO classifications.
  • BM and PB sampling for MRD evaluations study. Detailed indications on patient registration, storage of representative diagnostic material and diagnostic work-up, including the shipping of samples for the diagnostic work-up and MRD follow-up studies are given in Appendix A.
  • An ECOG performance status 0-2, unless a performance of 3 is unequivocally caused by the disease itself, (and not by pre-existing comorbidities,) and is considered and/or documented to be reversible following the application of anti-leukemic therapy and appropriate supportive measures.

Exclusion Criteria:

  • Diagnosis of Burkitt's leukemia/lymphoma, CD19- BCP ALL, Ph+ ALL, T-ALL, lymphoblastic lymphoma (BM involvement by blast cells <25%).
  • Active CNS leukemia documented by diagnostic lumbar puncture on days -1 to -5 prior to the first blinatumomab administration, or any other clinical sign or symptom ascribable to symptomatic/documented CNS disease at time of each planned blinatumomab course.
  • Down's syndrome.
  • A pre-existing, uncontrolled pathology such as heart failure (congestive/ischemic, acute myocardial infarction within the past 3 months, untreatable arrhythmias, NYHA classes III and IV), severe liver disease with serum bilirubin >3 mg/dL and/or ALT >3 x upper normal limit (unless attributable to ALL), kidney function impairment with serum creatinine >2 mg/dL (unless attributable to ALL), and severe neuropsychiatric disorder that impairs the patient's ability to understand and sign the informed consent, or to cope with the intended treatment plan. N.B. For altered liver and kidney function tests, eligibility criteria can be reassessed at 24-96 hours, following the institution of adequate supportive measures.
  • Presence of serious, active, uncontrolled infections.
  • Pre-existing HIV positive serology (i.e. already known before enrolment). If HIV positivity is detected after enrolment, the patient is put off study.
  • A history of cancer that is not in a remission phase following surgery and/or radiotherapy and/or chemotherapy, with a life expectancy <1 year.
  • Pregnancy declared by the patient, unless a decision is taken with the patient to induce a therapeutic abortion in order to carry on with the ALL therapy. A pregnancy test is performed at diagnosis, but does not preclude the enrolment into study. Fertile patients will be advised to adopt contraceptive methods while on treatment.

Sites / Locations

  • AOU Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI
  • U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno
  • Az.Ospedaliera S.G.Moscati
  • UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro
  • UOC di Ematologia - Istituto Tumori - Giovanni Paolo II
  • UOC Ematologia Ospedale " Monsignor Raffaele Dimiccoli"
  • Azienda Ospedaliera - Papa Giovanni XXIII
  • Istituto di Ematologia "Lorenzo e A. Seragnoli" - Policlinico S. Orsola - Malpighi
  • Comprensorio Sanitario di Bolzano - Azienda Sanitaria dell'Alto Adige - Ematologia e Centro TMO - Ospedale S.Maurizio
  • Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia
  • Divisione di Ematologia Ospedale A. Perrino
  • ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO
  • Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto"
  • S.C. Ematologia ASO S. Croce e Carle
  • Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio
  • IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente
  • UOC di Ematologia con trapianto Ospedale S. Maria Goretti
  • ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
  • Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST
  • A.O.U. - Policlinico G. Martino Messina Oncologia Medica - U.O.C. Ematologia
  • U.O. di Ematologia- Ospedale dell'Angelo - Mestre
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia
  • Ospedale Niguarda " Ca Granda" - SC Ematologia
  • U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele
  • UO Ematologia - AOU Policlinico di Modena
  • Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli"
  • Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia
  • S.C.D.U. Ematologia - Università del Piemonte Orientale Amedeo Avogadro
  • U.O. CTMO Ematologia - Osp. S.Francesco
  • S.C.D.U.Medicina Interna a indirizzo ematologico
  • Università degli Studi di Padova - Ematologia ed Immunologia Clinica
  • Oncoematologia -plesso ospedaliero "A. Tortora" di Pagani
  • Ospedali Riuniti "Villa Sofia-Cervello"
  • U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto - A.U. Policlinico "Paolo Giaccone"
  • Day Hospital dell'U.O.C di Ematologia e CTMO Padiglione 1
  • S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo
  • Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia
  • U.O. Ematologia Clinica - Azienda USL di Pescara
  • U.O. Ematologia - AUSL Ospedale G. da Saliceto
  • Dipartimento Oncologico - Ospedale S.Maria delle Croci
  • Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli"
  • Ospedale "Infermi"
  • Az. Ospedaliera "Sant' Andrea"-Università la Sapienza II Facoltà di Medicina e Chirurgia
  • Complesso Ospedaliero S. Giovanni Addolorata
  • Padiglione Cesalpino - I piano - Divisione di Ematologia - Ospedale S. Camillo
  • S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena
  • U.O.C. Ematologia - Ospedale S. Eugenio
  • Università Cattolica del Sacro Cuore - Policlinico A. Gemelli
  • Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari - Divisione di Ematologia
  • Università degli Studi - Policlinico di Tor Vergata
  • Sezione di Ematologia Cancer Center Humanitas
  • UOC di Ematologia - AOU San Giovanni di Dio e Ruggi D'Aragona
  • Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza
  • U.O.C. Ematologia - A.O. Senese - Policlinico " Le Scotte"
  • U.O.C. di Ematologia - A.O. " SS Annunziata" - P.O. S.G. Moscati
  • Divisione di Ematologia dell'Università di Torino - "Città della Salute e della Scienza"
  • Ematologia e Terapie Cellulari- A.S.O. Ordine Mauriziano, P.O. Umberto I-Ospedale
  • S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista
  • Struttura Complessa Ematologia - Azienda Ospedaliera Universitaria Integrata-Ospedale Maggiore
  • Clinica Ematologica-Centro Trapianti e Terapie cellulari AOU,
  • Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi
  • ULSS N.6 Osp. S. Bortolo

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Chemotherapy + Blinatumomab

Arm Description

Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.

Outcomes

Primary Outcome Measures

Number of patients that obtain a negative Minimal Residual Disease (MRD)

Secondary Outcome Measures

Number of patients in complete remission (CR)
Number of patients that reach disease-free survial
Number of patients that relapse
Number of patients that dye due to treatment
Treatment-related mortality
Number of serious adverse events
Safety

Full Information

First Posted
December 5, 2017
Last Updated
January 3, 2022
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
search

1. Study Identification

Unique Protocol Identification Number
NCT03367299
Brief Title
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
Acronym
LAL2317
Official Title
National Treatment Program With Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell Precursor Adult Acute Lymphoblastic Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 8, 2018 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
February 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The present study aims at analyzing the response to treatment of adult patients homogeneously treated with supportive care, chemotherapy and blinatumomab.
Detailed Description
Eligible patients with CD19+ Ph- BCP ALL (Philadelphia-negative B-cell precursor acute lymphoblastic leukemia) will receive homogeneous supportive care, chemotherapy and blinatumomab immunotherapy, and will be homogeneously analyzed for response at prefixed time points from induction day 1. For risk-oriented therapy, patients in complete remission (CR) will be stratified by risk class according to the diagnostic characteristics and MRD (minimal residual disease) study results during early consolidation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor
Keywords
Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor, Adults, Minimal residual disease, Blinatumomab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
149 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Chemotherapy + Blinatumomab
Arm Type
Experimental
Arm Description
Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.
Intervention Type
Drug
Intervention Name(s)
Chemotherapy + Blinatumomab
Intervention Description
Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
Primary Outcome Measure Information:
Title
Number of patients that obtain a negative Minimal Residual Disease (MRD)
Time Frame
At week 14 from study entry
Secondary Outcome Measure Information:
Title
Number of patients in complete remission (CR)
Time Frame
At 32 months from study entry
Title
Number of patients that reach disease-free survial
Time Frame
At 32 months from study entry
Title
Number of patients that relapse
Time Frame
At 32 months from study entry
Title
Number of patients that dye due to treatment
Description
Treatment-related mortality
Time Frame
At 32 months from study entry
Title
Number of serious adverse events
Description
Safety
Time Frame
At 32 months from study entry

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed written informed consent according to ICH/EU/GCP and national local laws. Age 18-65 years. A diagnosis of untreated Ph- CD19+ BCP ALL is required, either de novo or secondary to chemo-radiotherapy for another cancer. Pre-treatment with low-dose corticosteroids in patients presenting with hyperleukocytosis is allowed. Before enrolment and pre-phase is allowed only in patients presenting with severe, potentially life-threatening disease-related clinical symptoms. All diagnostic procedures need to be performed on freshly obtained bone marrow (BM) and peripheral blood (PB) samples. Full cytological, cytochemical, immunophenotypic, cytogenetic and molecular disease characterization according to the EGIL and WHO classifications. BM and PB sampling for MRD evaluations study. Detailed indications on patient registration, storage of representative diagnostic material and diagnostic work-up, including the shipping of samples for the diagnostic work-up and MRD follow-up studies are given in Appendix A. An ECOG performance status 0-2, unless a performance of 3 is unequivocally caused by the disease itself, (and not by pre-existing comorbidities,) and is considered and/or documented to be reversible following the application of anti-leukemic therapy and appropriate supportive measures. Exclusion Criteria: Diagnosis of Burkitt's leukemia/lymphoma, CD19- BCP ALL, Ph+ ALL, T-ALL, lymphoblastic lymphoma (BM involvement by blast cells <25%). Active CNS leukemia documented by diagnostic lumbar puncture on days -1 to -5 prior to the first blinatumomab administration, or any other clinical sign or symptom ascribable to symptomatic/documented CNS disease at time of each planned blinatumomab course. Down's syndrome. A pre-existing, uncontrolled pathology such as heart failure (congestive/ischemic, acute myocardial infarction within the past 3 months, untreatable arrhythmias, NYHA classes III and IV), severe liver disease with serum bilirubin >3 mg/dL and/or ALT >3 x upper normal limit (unless attributable to ALL), kidney function impairment with serum creatinine >2 mg/dL (unless attributable to ALL), and severe neuropsychiatric disorder that impairs the patient's ability to understand and sign the informed consent, or to cope with the intended treatment plan. N.B. For altered liver and kidney function tests, eligibility criteria can be reassessed at 24-96 hours, following the institution of adequate supportive measures. Presence of serious, active, uncontrolled infections. Pre-existing HIV positive serology (i.e. already known before enrolment). If HIV positivity is detected after enrolment, the patient is put off study. A history of cancer that is not in a remission phase following surgery and/or radiotherapy and/or chemotherapy, with a life expectancy <1 year. Pregnancy declared by the patient, unless a decision is taken with the patient to induce a therapeutic abortion in order to carry on with the ALL therapy. A pregnancy test is performed at diagnosis, but does not preclude the enrolment into study. Fertile patients will be advised to adopt contraceptive methods while on treatment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Renato Bassan
Organizational Affiliation
Azienda ULSS 12 "Veneziana" U.O. Ematologia Direttore Renato Bassan
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Roberto Foà
Organizational Affiliation
Policlinico Umberto I, Hematology Department.
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Alessandro Rambaldi
Organizational Affiliation
Ospedale di Bergamo
Official's Role
Study Director
Facility Information:
Facility Name
AOU Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI
City
Ancona
Country
Italy
Facility Name
U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno
City
Ascoli Piceno
Country
Italy
Facility Name
Az.Ospedaliera S.G.Moscati
City
Avellino
Country
Italy
Facility Name
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro
City
Bari
Country
Italy
Facility Name
UOC di Ematologia - Istituto Tumori - Giovanni Paolo II
City
Bari
Country
Italy
Facility Name
UOC Ematologia Ospedale " Monsignor Raffaele Dimiccoli"
City
Barletta
Country
Italy
Facility Name
Azienda Ospedaliera - Papa Giovanni XXIII
City
Bergamo
Country
Italy
Facility Name
Istituto di Ematologia "Lorenzo e A. Seragnoli" - Policlinico S. Orsola - Malpighi
City
Bologna
Country
Italy
Facility Name
Comprensorio Sanitario di Bolzano - Azienda Sanitaria dell'Alto Adige - Ematologia e Centro TMO - Ospedale S.Maurizio
City
Bolzano
Country
Italy
Facility Name
Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia
City
Brescia
Country
Italy
Facility Name
Divisione di Ematologia Ospedale A. Perrino
City
Brindisi
Country
Italy
Facility Name
ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO
City
Cagliari
Country
Italy
Facility Name
Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto"
City
Catania
Country
Italy
Facility Name
S.C. Ematologia ASO S. Croce e Carle
City
Cuneo
Country
Italy
Facility Name
Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio
City
Firenze
Country
Italy
Facility Name
IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente
City
Genova
Country
Italy
Facility Name
UOC di Ematologia con trapianto Ospedale S. Maria Goretti
City
Latina
Country
Italy
Facility Name
ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
City
Lecce
Country
Italy
Facility Name
Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST
City
Meldola
Country
Italy
Facility Name
A.O.U. - Policlinico G. Martino Messina Oncologia Medica - U.O.C. Ematologia
City
Messina
Country
Italy
Facility Name
U.O. di Ematologia- Ospedale dell'Angelo - Mestre
City
Mestre
Country
Italy
Facility Name
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia
City
Milano
Country
Italy
Facility Name
Ospedale Niguarda " Ca Granda" - SC Ematologia
City
Milano
Country
Italy
Facility Name
U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele
City
Milano
Country
Italy
Facility Name
UO Ematologia - AOU Policlinico di Modena
City
Modena
Country
Italy
Facility Name
Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli"
City
Napoli
Country
Italy
Facility Name
Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia
City
Napoli
Country
Italy
Facility Name
S.C.D.U. Ematologia - Università del Piemonte Orientale Amedeo Avogadro
City
Novara
Country
Italy
Facility Name
U.O. CTMO Ematologia - Osp. S.Francesco
City
Nuoro
Country
Italy
Facility Name
S.C.D.U.Medicina Interna a indirizzo ematologico
City
Orbassano
Country
Italy
Facility Name
Università degli Studi di Padova - Ematologia ed Immunologia Clinica
City
Padova
Country
Italy
Facility Name
Oncoematologia -plesso ospedaliero "A. Tortora" di Pagani
City
Pagani
Country
Italy
Facility Name
Ospedali Riuniti "Villa Sofia-Cervello"
City
Palermo
Country
Italy
Facility Name
U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto - A.U. Policlinico "Paolo Giaccone"
City
Palermo
Country
Italy
Facility Name
Day Hospital dell'U.O.C di Ematologia e CTMO Padiglione 1
City
Parma
Country
Italy
Facility Name
S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo
City
Pavia
Country
Italy
Facility Name
Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia
City
Perugia
Country
Italy
Facility Name
U.O. Ematologia Clinica - Azienda USL di Pescara
City
Pescara
Country
Italy
Facility Name
U.O. Ematologia - AUSL Ospedale G. da Saliceto
City
Piacenza
Country
Italy
Facility Name
Dipartimento Oncologico - Ospedale S.Maria delle Croci
City
Ravenna
Country
Italy
Facility Name
Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli"
City
Reggio Calabria
Country
Italy
Facility Name
Ospedale "Infermi"
City
Rimini
Country
Italy
Facility Name
Az. Ospedaliera "Sant' Andrea"-Università la Sapienza II Facoltà di Medicina e Chirurgia
City
Roma
Country
Italy
Facility Name
Complesso Ospedaliero S. Giovanni Addolorata
City
Roma
Country
Italy
Facility Name
Padiglione Cesalpino - I piano - Divisione di Ematologia - Ospedale S. Camillo
City
Roma
Country
Italy
Facility Name
S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena
City
Roma
Country
Italy
Facility Name
U.O.C. Ematologia - Ospedale S. Eugenio
City
Roma
Country
Italy
Facility Name
Università Cattolica del Sacro Cuore - Policlinico A. Gemelli
City
Roma
Country
Italy
Facility Name
Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari - Divisione di Ematologia
City
Roma
Country
Italy
Facility Name
Università degli Studi - Policlinico di Tor Vergata
City
Roma
Country
Italy
Facility Name
Sezione di Ematologia Cancer Center Humanitas
City
Rozzano
Country
Italy
Facility Name
UOC di Ematologia - AOU San Giovanni di Dio e Ruggi D'Aragona
City
Salerno
Country
Italy
Facility Name
Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza
City
San Giovanni Rotondo
Country
Italy
Facility Name
U.O.C. Ematologia - A.O. Senese - Policlinico " Le Scotte"
City
Siena
Country
Italy
Facility Name
U.O.C. di Ematologia - A.O. " SS Annunziata" - P.O. S.G. Moscati
City
Taranto
Country
Italy
Facility Name
Divisione di Ematologia dell'Università di Torino - "Città della Salute e della Scienza"
City
Torino
Country
Italy
Facility Name
Ematologia e Terapie Cellulari- A.S.O. Ordine Mauriziano, P.O. Umberto I-Ospedale
City
Torino
Country
Italy
Facility Name
S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista
City
Torino
Country
Italy
Facility Name
Struttura Complessa Ematologia - Azienda Ospedaliera Universitaria Integrata-Ospedale Maggiore
City
Trieste
Country
Italy
Facility Name
Clinica Ematologica-Centro Trapianti e Terapie cellulari AOU,
City
Udine
Country
Italy
Facility Name
Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi
City
Verona
Country
Italy
Facility Name
ULSS N.6 Osp. S. Bortolo
City
Vicenza
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Links:
URL
http://www.gimema.it
Description
GIMEMA Foundation website

Learn more about this trial

Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

We'll reach out to this number within 24 hrs